There are currently 87 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
Study of CAR-T Therapy in Older Patients
NCT04300998
Recruiting
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
06/10/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS, High-grade B-cell Lymphoma, Multiple Myeloma
Register for Updates
A Study of Mosunetuzumab in People With Follicular Lymphoma
NCT05389293
Recruiting
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Georgetown University (Data Collection Only), Washington, District of Columbia +8 locations
Conditions: Follicular Lymphoma, Lymphoma
Register for Updates
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
NCT05898477
Recruiting
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
Gender:
ALL
Ages:
All
Trial Updated:
06/07/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Lymphoma, Hemophagocytic Lymphohistiocytoses
Register for Updates
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
NCT06371768
Recruiting
The purpose of this study is to determine the effectiveness of a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and engage in recommended follow-up care.
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
06/06/2025
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Cancer, Breast Cancer, Colorectal Cancer, Sarcoma, Lymphoma, Testicular Cancer
Register for Updates
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
NCT05464719
Recruiting
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Large B-cell Lymphoma, Lymphoma
Register for Updates
Sample Collection and Tracking for the Developmental Therapeutics Clinic
NCT03269578
Recruiting
Background: People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. Researchers want to access people s medical records. This will allow them to link the research data from all their studies they have or will take part in. Researchers also want to collect medical data... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/06/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Lymphoma
Register for Updates
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
NCT05346809
Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Karmanos Cancer Institute, Detroit, Michigan +1 locations
Conditions: Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
Register for Updates
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
NCT05683171
Recruiting
To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085
Recruiting
The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: UC San Diego Moores Cancer Center, La Jolla, California +9 locations
Conditions: Lymphoma
Register for Updates
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936
Recruiting
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Alta Bates Summit Medical Center, Berkeley, California +73 locations
Conditions: Lymphoma
Register for Updates
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
NCT06326463
Recruiting
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
06/02/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma, MDS
Register for Updates
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
NCT06680661
Recruiting
The goal of this clinical trial is to see if adding abatacept to tacrolimus and MMF prevents or reduces the chances of acute graft versus host disease which is a complication that can occur after transplant in participants with blood cancer. The usual therapy for graft versus host disease prevention after a cord blood transplant includes tacrolimus and MMF. The main question this clinical trial aims to answer is whether or not abatacept will be safe and effective in reducing aGVHD rates in dCBT.... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/02/2025
Locations: University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myelodysplastic Syndrome Other, Chronic Myelomonocytic Leukemia, Lymphoma, Hodgkin Lymphoma
Register for Updates